We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+26.78%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$144M
AUM Growth
+$18.8M
Cap. Flow
-$7.43M
Cap. Flow %
-5.14%
Top 10 Hldgs %
90.35%
Holding
19
New
3
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$3.35M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.26M
3
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$2.18M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$8.57M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$6.04M
3
CBAY
Cymabay Therapeutics
CBAY
+$387K
4
NOVN
Novan, Inc. Common Stock
NOVN
+$215K

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.73B
$35.1M 24.33%
1,971,907
-472,902
-19% -$8.57M
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$33.8M 23.42%
219,901
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$26.1M 18.09%
1,041,131
-259,301
-20% -$6.04M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$12.4M 8.6%
1,542,722
-57,278
-4% -$387K
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.31M 3.67%
2,080,595
– –
TARA icon
6
Protara Therapeutics
TARA
$220M
$3.94M 2.72%
50,447
– –
CASC
7
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.78M 2.62%
925,000
– –
IMDZ
8
DELISTED
Immune Design Corp.
IMDZ
$3.65M 2.52%
352,300
– –
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.48M 2.41%
+440,000
New +$3.35M
CLLS
10
Cellectis
CLLS
$277M
$2.84M 1.97%
100,000
– –
ONCT
11
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$2.78M 1.93%
+2,423
New +$2.18M
ADAP
12
DELISTED
Adaptimmune Therapeutics
ADAP
$2.04M 1.42%
250,000
– –
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.45B
$2.03M 1.4%
+38,100
New +$2.26M
DERM
14
DELISTED
Dermira, Inc.
DERM
$1.89M 1.31%
70,000
– –
OCGN icon
15
Ocugen
OCGN
$416M
$1.76M 1.22%
14,815
– –
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.58M 1.09%
252,129
– –
EVAR
17
DELISTED
Lombard Medical, Inc.
EVAR
$1.53M 1.06%
3,473,452
– –
INNL
18
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$322K 0.22%
537,235
– –
NOVN
19
DELISTED
Novan, Inc. Common Stock
NOVN
– –
-5,337
Closed -$215K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2017 Portfolio in Review

As of Q3 2017, Abingworth held 19 positions worth $144M, up 15% from $126M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Abingworth withdrew a net $7.43M in Q3 2017, closing 1 position and reducing 3 holdings. Its most notable exit was Novan, Inc. Common Stock, an estimated $215K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

Against the trend, Abingworth opened a new position in ObsEva SA Ordinary Shares worth $3.48M.

  • Abingworth's largest Q3 2017 buy was ObsEva SA Ordinary Shares: 440,000 shares worth $3.48M.
  • Abingworth's biggest Q3 2017 reduction was CRISPR Therapeutics, cutting an estimated $8.57M.
  • Abingworth fully exited Novan, Inc. Common Stock in Q3 2017, selling an estimated $215K.
  • Abingworth's ten largest holdings make up 90% of its $144M portfolio in Q3 2017.
  • Abingworth opened 3 new positions and closed 1 in Q3 2017.
  • Abingworth's portfolio value rose 15% quarter-over-quarter to $144M.

Based on Abingworth's 13F filing for Q3 2017, filed 14 Nov 2017.